Human leukocyte antigen (HLA) B44 supertype and immunotherapy outcomes in non-small cell lung cancer (NSCLC).

Authors

null

Henry Lu

University of Virginia School of Medicine, Charlottesville, VA

Henry Lu , Amy Lauren Cummings , Jonathan Wade Goldman , Aaron Elliott Lisberg , Siwen Hu-Lieskovan , Tristan Grogan , Jaklin Gukasyan , John Madrigal , James M. Carroll , Krikor Bornazyan , Benjamin Jones , Zorawar Singh Noor , Jesse Meir Zaretsky , David Elashoff , Dennis J. Slamon , Steven M. Dubinett , Edward B. Garon

Organizations

University of Virginia School of Medicine, Charlottesville, VA, David Geffen School of Medicine at UCLA, Los Angeles, CA, UCLA Medical Center, Los Angeles, CA, UCLA, Los Angeles, CA, UCLA's Jonsson Comprehensive Cancer Center, Los Angeles, CA, University of California, Los Angeles, Los Angeles, CA, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA, Univ of California Irvine, Orange, CA

Research Funding

NIH

Background: In melanoma (mel) patients (pts) treated with immune checkpoint inhibitors, presence of HLA class I (HLA-1) B44 supertype (B44+) correlated with survival (Chowell, Science). B44 preferentially binds negatively charged (neg) peptides and those with glutamic acid (E) at the anchor position. Positively charged (pos) peptides impede binding. In mel, B44 benefit was driven by glycine (G) > E changes. We evaluated the predictive role of HLA-I supertypes in NSCLC as neoepitopes are likely different as tranversions (Tv) predominate in smokers compared to transitions (Ti) in mel. Methods: 58 advanced NSCLC pts treated with pembrolizumab with 3 years follow up and sufficient PBMCs and/or tumor sample had multiplexed paired-end WES with Illumina HiSeq 2000/3000. HLA typing used BWA-ALN and Athlates software; supertype was determined by 2008 criteria (Sidney, BMC Immunol). Overall survival (OS) and progression-free survival (PFS) were compared by supertype using non-parametric log-rank tests. Tumor variant amino acids (vAA) were identified by GATK best practices, and AA charge was derived from standard charts with stop codons considered uncharged (unc). Ti/Tv and charge change analysis used two-proportion z-tests. Statistical analyses were performed with SPSS V24 (Armonk, NY). Results: Of 9 supertypes evaluated, only absence of B44 supertype (B44-) had longer OS [median OS of 14.9 months (m) vs 9.2 m in B44+ (HR 0.55, 95% CI 0.30-0.99, p = 0.048)], driven by B44- smokers [median OS 21.5 m vs 8.5 m in all other pts (HR 0.50, 95% CI 0.26-0.995, p = 0.048)]. PFS and response rate trends were similar to OS. vAA charge changes from unc/pos to neg in 14/384 (3.6%) Tv and 8/192 (4.2%) Ti (NS) and from unc/neg to pos in 48/384 (12.5%) Tv vs 12/192 (6.3%) Ti (p = 0.019). G > E is not possible from Tv. Among pts with evaluated tumors, Ti/Tv, vAA charge, and G > E were as predicted. Conclusions: Like mel, the B44 supertype associates with OS in NSCLC, however with the opposite effect direction, driven by favorable OS in B44- smokers. A potential mechanism for these histology-specific results is the greater likelihood of Tv in smokers that may lead to neoepitopes with characteristics less favorable for presentation on HLA B44.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics and Translational Research

Sub Track

Biomarkers and Correlative Studies from Immunotherapy Trials

Citation

J Clin Oncol 36, 2018 (suppl; abstr 3026)

DOI

10.1200/JCO.2018.36.15_suppl.3026

Abstract #

3026

Poster Bd #

240

Abstract Disclosures